Advertisement

Foundations acquire a critical new role as federal funding for cancer research falters

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The fight against cancer is complex. It’s global. And it’s indisputably expensive. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Ryan Schoenfeld, PhD
CEO, The Mark Foundation
Raymond N. DuBois, MD, PhD
Executive chair of the board, The Mark Foundation; Director, Medical University of South Carolina Hollings Cancer Center; Past dean of Medicine, the Medical University of South Carolina
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
Advertisement
Advertisement